SCHEMBL3616375

SCHEMBL3616375

COC(=O)C(CC1CCC(O[Si](C)(C)C(C)(C)C)CC1)NC(=O)OC(C)(C)C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSK P43235 3/20 0.50
CTSS P25774 2/20 0.50
AAK1 Q2M2I8 2/20 0.41
CACNA1B Q00975 4/20 0.38
NFKB1 P19838 2/20 0.37
NFKB2 Q00653 2/20 0.37
RELA Q04206 2/20 0.37
GSTP1 P09211 1/20 0.37
GSTM2 P28161 1/20 0.37
KMT2A Q03164 1/20 0.37
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
HTT P42858 1/20 0.36
CNR2 P34972 2/20 0.36
ITGB3 P05106 1/20 0.35
ITGA2B P08514 1/20 0.35
HDAC4 P56524 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3616378 1.00 CTSK (0.50) CTSKCTSSAAK1CACNA1BNFKB1
SCHEMBL4970239 0.87 CNR2 (0.38) CTSKCTSSCNR2
SCHEMBL3594507 0.87 CNR2 (0.38) CTSKCTSSCNR2
SCHEMBL6078092 0.86 CTSS (0.63) CTSKCTSSAAK1CACNA1BNFKB1
SCHEMBL14151599 0.86 CTSS (0.63) CTSKCTSSAAK1CACNA1BNFKB1
SCHEMBL7084925 0.86 CTSS (0.63) CTSKCTSSAAK1CACNA1BNFKB1
SCHEMBL3605408 0.82 CTSK (0.43) CTSKCTSSAAK1CACNA1BKMT2A
SCHEMBL1861343 0.82 CTSK (0.43) CTSKCTSSAAK1CACNA1BKMT2A
SCHEMBL16574695 0.82 CTSK (0.64) CTSKCTSSAAK1CACNA1BKMT2A
SCHEMBL16228708 0.81 CTSS (0.57) CTSKCTSSAAK1CACNA1BNFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8487108-B2 Piperidinyl carbamate intermediates for the synthesis of aspartic protease inhibitors VITAE PHARMACEUTICALS, INC. (US) 2013-07-16 US disclosed
EP-1966139-B1 ASPARTIC PROTEASE INHIBITORS VITAE PHARMACEUTICALS INC (US) 2011-12-21 EP disclosed
US-20100048636-A1 Aspartic Protease Inhibitors VITAE PHARMACEUTICALS, INC. 2010-02-25 US disclosed
EP-1966139-A1 ASPARTIC PROTEASE INHIBITORS Vitae Pharmaceuticals, Inc. (US) 2008-09-10 EP disclosed
WO-2007070201-A1 ASPARTIC PROTEASE INHIBITORS VITAE PHARMACEUTICALS, INC. (US) 2007-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048636-A1 Aspartic Protease Inhibitors DNPEP, PEPD, SERPINB1 CTSK 152/4885CTSS 95/4885AAK1 2635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.